[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Morten Hostrup, PhD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":125},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,74,95,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100625314","phase-2-biased-grk-signaling-via-2-adrenergic-receptors-in-human-skeletal-muscle-100625314",false,"NCT07421024","Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle","Biased G Protein-Coupled Receptor Kinase Signaling Via β2-Adrenergic Receptors and Downstream Activation of Protein Synthesis-Regulating Kinases and Receptor Desensitization in Human Skeletal Muscle","ATR","Inclusion Criteria:\n\n* Healthy men\n* Age 21-45 years\n* BMI 25-35 kg\u002Fm\\^2\n* Body fat percentage 25-40%\n* Lean Mass Index 14-22\n\nExclusion Criteria:\n\n* Regular use of or allergy to β2-agonists\n* Serious adverse reactions to β2-agonists\n* Current smoker\n* Regular use of medication (except OTC allergy or analgesics)\n* Abnormal ECG before or after β2-AR stimulation\n* Hypertension\n* Reduced kidney function (eGFR \\\u003C 90 ml\u002Fmin\u002F1.73m\\^2)\n* Cardiovascular, metabolic, gastrointestinal, renal, or pulmonary disease\n* Psychiatric or neurological disorders affecting compliance\u002Fsafety reporting\n* Cancer history within the last 5 years\n* Substance abuse or alcohol intake \\>14 units\u002Fweek",true,"MALE","21 Years","45 Years",{"count":22,"type":23},10,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","This longitudinal mechanistic physiological study examines biased β2-adrenergic receptor (β2-AR) signaling in human skeletal muscle, with emphasis on G protein-coupled receptor kinase (GRK)-mediated pathways. Participants will receive daily oral dosing of the GRK-selective long-acting β2-agonist ATR-258 for 8 weeks. Muscle biopsies and physiological measurements will quantify GRK-, cAMP\u002FPKA-, and β-arrestin-related signaling, fiber-type specificity, and potential receptor desensitization with repeated stimulation.",[29],"Overweight and Obesity",[31,32,33,34,35],"beta2","muscle","atr-258","adrenergic","biased signaling","NOT_YET_RECRUITING","2026-02-16",{"date":39,"type":40},"2026-02-19","ACTUAL",{"date":42,"type":23},"2026-02-20",{"date":44,"type":23},"2026-12-31",{"name":46,"class":47},"Morten Hostrup, PhD","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":48},"100530591","testosterone-induced-muscle-memory-and-underlying-mechanisms-100530591","NCT06188767","Testosterone-induced Muscle Memory and Underlying Mechanisms","Long-term Effects of Anabolic Androgenic Steroids on Muscle Growth Potential: Testosterone-induced Muscle Memory and Underlying Mechanisms","Inclusion Criteria:\n\n* Healthy men and women\n* BMI of \\\u003C26 and normal ECG and blood pressure\n\nExclusion Criteria:\n\n* Smoking\n* Chronic disease,\n* Use of prescription medication\n* Pain due to current or previous musculoskeletal injury\n* Resistance training more than once per week in the 12 months leading up to the intervention\n* Current or previous use of prohibited anabolic substances","18 Years","40 Years",{"count":59,"type":23},30,[61],"NA","The purpose of this project is to investigate underlying mechanisms of testosterone- and resistance training-induced muscle hypertrophy and muscle memory in humans.",[64],"Skeletal Muscle Physiology","RECRUITING","2025-04-07",{"date":68,"type":40},"2025-04-10",{"date":70,"type":40},"2025-04-01",{"date":72,"type":23},"2028-12-01",{"name":46,"class":47},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":17,"sex":81,"minAge":56,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":48},"100521246","u-labaics-effects-on-exercise-performance-indacaterol-100521246","NCT06067100","U-LABA\u002FICS Effects on Exercise Performance, Indacaterol","Physiological Response to U-LABA\u002FICS With Emphasis on Exercise Performance, Indacaterol","Inclusion Criteria:\n\n* Age 18-39\n* Physically active \\> 5 h weekly\n* Maximal oxygen consumption classified as high or very high\n\nExclusion Criteria:\n\n* Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist\u002Fcorticosteroid\n* ECG abnormality\n* ACQ score \\> 1.5\n* Severe bronchial hyperreactivity as determined by mannitol test\n* FEV1\u002FFVC ratio \\\u003C 0.7 determined with spirometry\n* Chronic illness determined to be a potential risk for participant during study\n* In chronic treatment with medication that may interfere with study results\n* Pregnancy\n* Smoker\n* Blood donation during the past 3 months","ALL","39 Years",{"count":59,"type":23},[61],"The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist indacaterol + mometasonefuroate",[87],"Exercise Performance",{"date":89,"type":40},"2025-04-09",{"date":91,"type":40},"2024-01-15",{"date":93,"type":23},"2026-12-01",{"name":46,"class":47},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":17,"sex":81,"minAge":56,"maxAge":82,"enrollmentInfo":101,"targetDuration":4,"studyType":24,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":109,"locationsCount":48},"100521208","u-labaics-effects-on-exercise-performance-vilanterol-100521208","NCT06066606","U-LABA\u002FICS Effects on Exercise Performance, Vilanterol","Physiological Response to U-LABA\u002FICS With Emphasis on Exercise Performance, Vilanterol",{"count":59,"type":23},[61],"The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate",[87],{"date":68,"type":40},{"date":107,"type":40},"2023-10-03",{"date":93,"type":23},{"name":46,"class":47},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":17,"sex":81,"minAge":56,"maxAge":82,"enrollmentInfo":116,"targetDuration":4,"studyType":24,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":123,"leadSponsor":124,"locationsCount":48},"100522009","role-of-lung-function-for-exercise-capacity-in-well-trained-individuals-100522009","NCT06077019","Role of Lung Function for Exercise Capacity in Well-trained Individuals","Role of Lung Function, Airway Inflammation and Bronchial Hyper Reactivity for Exercise Capacity in Well-trained Individuals",{"count":117,"type":23},60,[61],"The purpose of the project is to investigate exercise performance in humans following prolonged inhalation of beta2-agonists vilanterol + fluticasone furoate or indacaterol + mometasone furoate",[87],{"date":89,"type":40},{"date":107,"type":40},{"date":93,"type":23},{"name":46,"class":47},""]